Understanding how the body controls the reactivation of Epstein-Barr virus
Defining host mechanisms that restrict EBV lytic reactivation
This study is looking at how our immune system keeps the Epstein-Barr virus from causing problems, especially in people with weaker immune systems, to help find better ways to manage illnesses related to this virus.
Quick facts
| Grant type | Fellowship grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Duke University NIH-funded |
| Lab location | 1 site (Durham, United States) |
| Project ID | NIH-10994060 on NIH RePORTER |
What this research studies
This research investigates how the Epstein-Barr virus (EBV), which can cause serious health issues in some individuals, is kept in check by the body's immune system. The study focuses on the mechanisms that prevent the virus from reactivating and causing diseases, particularly in people with weakened immune systems. By analyzing the responses of B cells to various stimuli that can trigger the virus, researchers aim to uncover why some cells reactivate the virus while others do not. This could lead to new strategies for managing EBV-related diseases.
Who could benefit from this research
Good fit: Ideal candidates for this research include individuals with a history of Epstein-Barr virus infection, especially those who are immunocompromised or have experienced EBV-related health issues.
Not a fit: Patients who have never been infected with Epstein-Barr virus or those with fully functioning immune systems may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to improved treatments for EBV-related diseases, particularly in immunocompromised patients.
How similar studies have performed: Previous research has shown promising results in understanding viral reactivation mechanisms, suggesting that this approach could yield valuable insights.
Where this research is happening
Durham, United States
- Duke University — Durham, United States (Active)
Researchers
- Principal investigator: Haynes, Lauren — Duke University
- Study coordinator: Haynes, Lauren
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.